PT109 is a multi-kinase inhibitor. PT109 inhibits JNK ( JNK1 : IC 50 =0.143 μM; JNK2 : IC 50 =0.831 μM; JNK3 : IC 50 =0.285 μM) and other kinases ( SGK1 : IC 50 =1.34 μM; SGK2 : IC 50 =5.6 μM; SGK3 : IC 50 =26.4 μM; ROCK2 : IC 50 =34 μM) and plays an important role in anti-inflammation, anti-oxidation, neurogenesis, synaptogenesis, etc. In addition, PT109 also reprograms glioblastoma multiforme (GBM) into oligodendrocytes through the PTBP1/PKM1/2 pathway and changes the metabolic pattern of GBM, exerting anti-glioma activity.